Differential expression profile of hepatic circular RNAs in chronic hepatitis B

T-C Zhou1, X Li1, L-J Chen1

  • 1Central lab, Liver disease research center, the Second People's Hospital of Yunnan Province, Kunming, China.

Insights

Circular RNAs (circRNAs) show distinct expression patterns in chronic hepatitis B (CHB) patients, impacting disease progression. These findings highlight circRNAs as potential biomarkers and therapeutic targets for CHB.

Area of Science:

  • Molecular Biology
  • Hepatology
  • Genomics

Background:

  • Circular RNAs (circRNAs) are key gene regulators, influencing disease development.
  • Limited understanding of circRNA roles in chronic hepatitis B (CHB) and healthy states.

Purpose of the Study:

  • To identify hepatic circRNAs associated with CHB.
  • To analyze circRNA-miRNA-mRNA pathways in CHB pathogenesis.

Main Methods:

  • RNA sequencing of liver biopsies from CHB patients and controls.
  • Bioinformatics pipeline for circRNA identification and pathway analysis.
  • Quantitative reverse transcription polymerase chain reaction (qRT-PCR) for validation.

Main Results:

  • Significant differences in hepatic circRNA expression profiles between CHB patients and controls.
  • Identified 99 dysregulated circRNAs correlated with CHB.
  • Revealed 665 microRNAs (miRNAs) targeted by differentially expressed circRNAs.
  • Four circRNA-miRNA-mRNA pathways implicated in HBV infection and liver disease progression.
  • Discovered a specific pathway involving hsa_circ_0000650, miR-6873-3p, and TGFβ2.

Conclusions:

  • CHB patients exhibit unique hepatic circRNA expression and interaction profiles.
  • CircRNAs represent promising novel mechanisms in CHB pathogenesis and progression.
  • CircRNAs and their interactions offer potential as CHB biomarkers and therapeutic targets.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.1K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
248
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
596
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
311
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.8K